Search
Welcome
  • Login
  • Register
Forgot Password?
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
Not a subscriber? Subscribe here
Register Now
  • Login
  • Register
Forgot Password?
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
                       
Careers & Tenders
Newsletters
Subscribe
The Mail & Guardian
      SUBSCRIBE / Support independent journalism                   CAREERS & TENDERS / Visit careers.mg.co.za                   WHATSAPP? / Follow the M&G WhatsApp channel here            
Login / Register

LOGIN

  • News
    • Africa
    • Business
    • Editorial
    • Education
    • Health
    • Motoring
    • National
    • Sci-tech
    • Sport
    • World
  • Thought Leader
  • Politics
  • Green Guardian
  • Friday
  • The Diplomat
  • G20 South Africa
  • Power of Women
  • Events
    • 200 Young South Africans
    • Greening The Future
    • Critical Thinking Forum
    • Youth Summit
    • Webinars
  • More..
    • Research World
    • Partners
    • Podcasts
    • Crossword
    • Digital Editions
    • Register
    • WhatsApp Channel
    • Login
    • Lost Password

           

Unitaid

SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them
Health
/ 2 December 2025

SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them

Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?

By Linda Pretorius and Jacques Verryn
SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch
Health
/ 1 December 2025

SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch

None of the companies that will be involved have a licence from the inventor of Lenacapavir, Gilead Sciences, to make the jab

By Mia Malan
Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill
Health
/ 29 September 2025

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill

Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year

By Mia Malan
After India: The countries on the brink of another Covid oxygen crisis
Coronavirus
/ 25 May 2021

After India: The countries on the brink of another Covid oxygen crisis

The need for medical oxygen to treat Covid-19 patients in low- and middle-income countries has more than doubled in the past two months, and many of these countries faced oxygen shortages before the pandemic

By Madlen Davies and Rosa Furneaux

MAIL & GUARDIAN

ABOUT

About
Contact
Advertise

SUBSCRIPTIONS

Subscribe
Newsletters

FOLLOW

WhatsApp Channel
Twitter
Facebook
YouTube
Instagram
LinkedIn
TikTok
Threads

FLAGSHIP EVENTS

200 Young South Africans
Power Of Women
Greening The Future

LEGAL & CORRECTIONS

Privacy Policy
Cookie Policy
Ethics & Social Media Policy

RESOURCES

Mail & Guardian Careers
Property for sale


Mail & Guardian

© 2025 The Mail & Guardian. All rights reserved.

  • Login
  • Register
Forgot Password?
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
body::-webkit-scrollbar { width: 7px; } body::-webkit-scrollbar-track { border-radius: 10px; background: #f0f0f0; } body::-webkit-scrollbar-thumb { border-radius: 50px; background: #dfdbdb }